Skip to main content
Top
Published in: Cost Effectiveness and Resource Allocation 1/2018

Open Access 01-12-2018 | Review

Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations

Authors: Leopold Ndemnge Aminde, Noah Fongwen Takah, Belen Zapata-Diomedi, J. Lennert Veerman

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2018

Login to get access

Abstract

Background

Cardiovascular disease (CVD) is the leading cause of deaths globally, with greatest premature mortality in the low- and middle-income countries (LMIC). Many of these countries, especially in sub-Saharan Africa, have significant budget constraints. The need for current evidence on which interventions offer good value for money to stem this CVD epidemic motivates this study.

Methods

In this systematic review, we included studies reporting full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. Several medical (PubMed, EMBASE, SCOPUS, Web of Science) and economic (EconLit, NHS EED) databases and grey literature were searched. Screening of studies and data extraction was done independently by two reviewers. Drummond’s checklist and the National Institute for Health and Care Excellence quality rating scale were used in the quality appraisal for all studies used to inform this evidence synthesis.

Results

From a pool of 4059 records, 94 full texts were read and 50 studies, which met our inclusion criteria, were retained for our narrative synthesis. Most of the studies were from middle-income countries and predominantly of high quality. The majority were modelled evaluations, and there was significant heterogeneity in methods. Primary prevention studies dominated secondary prevention. Most of the economic evaluations were performed for pharmacological interventions focusing on blood pressure, cholesterol lowering and antiplatelet aggregants. The greatest majority were cost-effective. Compared to individual-based interventions, population-based interventions were few and mostly targeted reduction in sodium intake and tobacco control strategies. These were very cost-effective with many being cost-saving.

Conclusions

This evidence synthesis provides a contemporary update on interventions that offer good value for money in LMICs. Population-based interventions especially those targeting reduction in salt intake and tobacco control are very cost-effective in LMICs with potential to generate economic gains that can be reinvested to improve health and/or other sectors. While this evidence is relevant for policy across these regions, decision makers should additionally take into account other multi-sectoral perspectives, including considerations in budget impact, fairness, affordability and implementation while setting priorities for resource allocation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.CrossRefPubMedPubMedCentral Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.CrossRefPubMedPubMedCentral
3.
go back to reference Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.CrossRefPubMed Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.CrossRefPubMed
5.
go back to reference Musgrove P, Fox-Rushby J. Cost-Effectiveness analysis for priority setting. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. Washington (DC)/New York: The International Bank for Reconstruction and Development/The World Bank and Oxford University Press; 2006. Musgrove P, Fox-Rushby J. Cost-Effectiveness analysis for priority setting. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. Washington (DC)/New York: The International Bank for Reconstruction and Development/The World Bank and Oxford University Press; 2006.
6.
go back to reference Edejer T-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003. Edejer T-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
7.
go back to reference Suhrcke M, Boluarte TA, Niessen L. A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries. BMC Public Health. 2012;12:2.CrossRefPubMedPubMedCentral Suhrcke M, Boluarte TA, Niessen L. A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries. BMC Public Health. 2012;12:2.CrossRefPubMedPubMedCentral
8.
go back to reference Mensah GA. Tackling noncommunicable diseases in Africa: caveat lector. Health Educ Behav. 2016;43(1 Suppl):7s–13s.CrossRefPubMed Mensah GA. Tackling noncommunicable diseases in Africa: caveat lector. Health Educ Behav. 2016;43(1 Suppl):7s–13s.CrossRefPubMed
9.
go back to reference Shroufi A, Chowdhury R, Anchala R, Stevens S, Blanco P, Han T, et al. Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review. BMC Public Health. 2013;13:285.CrossRefPubMedPubMedCentral Shroufi A, Chowdhury R, Anchala R, Stevens S, Blanco P, Han T, et al. Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review. BMC Public Health. 2013;13:285.CrossRefPubMedPubMedCentral
10.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral
11.
go back to reference Aminde LN, Veerman L. Interventions for the prevention of cardiovascular diseases: a protocol for a systematic review of economic evaluations in low-income and middle-income countries. BMJ Open. 2016;6(12):e013668.CrossRefPubMedPubMedCentral Aminde LN, Veerman L. Interventions for the prevention of cardiovascular diseases: a protocol for a systematic review of economic evaluations in low-income and middle-income countries. BMJ Open. 2016;6(12):e013668.CrossRefPubMedPubMedCentral
13.
go back to reference Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015.
16.
go back to reference Robberstad B, Hemed Y, Norheim OF. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country–the case of Tanzania. Cost Eff Resour Alloc. 2007;5:3.CrossRefPubMedPubMedCentral Robberstad B, Hemed Y, Norheim OF. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country–the case of Tanzania. Cost Eff Resour Alloc. 2007;5:3.CrossRefPubMedPubMedCentral
17.
go back to reference Ngalesoni FN, Ruhago GM, Mori AT, Robberstad B, Norheim OF. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study. BMC Health Serv Res. 2016;16:185.CrossRefPubMedPubMedCentral Ngalesoni FN, Ruhago GM, Mori AT, Robberstad B, Norheim OF. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study. BMC Health Serv Res. 2016;16:185.CrossRefPubMedPubMedCentral
18.
go back to reference Tolla MT, Norheim OF, Memirie ST, Abdisa SG, Ababulgu A, Jerene D, et al. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. Cost Eff Resour Alloc. 2016;14:10.CrossRefPubMedPubMedCentral Tolla MT, Norheim OF, Memirie ST, Abdisa SG, Ababulgu A, Jerene D, et al. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. Cost Eff Resour Alloc. 2016;14:10.CrossRefPubMedPubMedCentral
19.
go back to reference Gaziano T, Abrahams-Gessel S, Surka S, Sy S, Pandya A, Denman CA, et al. Cardiovascular disease screening by community health workers can be cost-effective in low-resource countries. Health Affairs. 2015;34(9):1538–45.CrossRefPubMedPubMedCentral Gaziano T, Abrahams-Gessel S, Surka S, Sy S, Pandya A, Denman CA, et al. Cardiovascular disease screening by community health workers can be cost-effective in low-resource countries. Health Affairs. 2015;34(9):1538–45.CrossRefPubMedPubMedCentral
20.
go back to reference Nguyen TP, Wright EP, Nguyen TT, Schuiling-Veninga CC, Bijlsma MJ, Nguyen TB, et al. Cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in Vietnam. PLoS ONE. 2016;11(5):e0155699.CrossRefPubMedPubMedCentral Nguyen TP, Wright EP, Nguyen TT, Schuiling-Veninga CC, Bijlsma MJ, Nguyen TB, et al. Cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in Vietnam. PLoS ONE. 2016;11(5):e0155699.CrossRefPubMedPubMedCentral
21.
go back to reference Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. BMC Cardiovasc Disord. 2010;10:13.CrossRefPubMedPubMedCentral Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. BMC Cardiovasc Disord. 2010;10:13.CrossRefPubMedPubMedCentral
22.
go back to reference Rosendaal NT, Hendriks ME, Verhagen MD, Bolarinwa OA, Sanya EO, Kolo PM, et al. Costs and cost-effectiveness of hypertension screening and treatment in adults with hypertension in rural Nigeria in the context of a health insurance program. PLoS ONE. 2016;11(6):e0157925.CrossRefPubMedPubMedCentral Rosendaal NT, Hendriks ME, Verhagen MD, Bolarinwa OA, Sanya EO, Kolo PM, et al. Costs and cost-effectiveness of hypertension screening and treatment in adults with hypertension in rural Nigeria in the context of a health insurance program. PLoS ONE. 2016;11(6):e0157925.CrossRefPubMedPubMedCentral
23.
go back to reference Mason H, Shoaibi A, Ghandour R, O’Flaherty M, Capewell S, Khatib R, et al. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. PLoS ONE. 2014;9(1):e84445.CrossRefPubMedPubMedCentral Mason H, Shoaibi A, Ghandour R, O’Flaherty M, Capewell S, Khatib R, et al. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. PLoS ONE. 2014;9(1):e84445.CrossRefPubMedPubMedCentral
24.
go back to reference Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health. 2011;8(5):1271–86.CrossRefPubMedPubMedCentral Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health. 2011;8(5):1271–86.CrossRefPubMedPubMedCentral
25.
go back to reference Wilcox ML, Mason H, Fouad FM, Rastam S, Al Ali R, Page TF, et al. Cost-effectiveness analysis of salt reduction policies to reduce coronary heart disease in Syria, 2010–2020. Int J Public Health. 2015;60(Suppl 1):S23–30.CrossRefPubMed Wilcox ML, Mason H, Fouad FM, Rastam S, Al Ali R, Page TF, et al. Cost-effectiveness analysis of salt reduction policies to reduce coronary heart disease in Syria, 2010–2020. Int J Public Health. 2015;60(Suppl 1):S23–30.CrossRefPubMed
26.
go back to reference Akkazieva B, Chisholm D, Akunov N, Jakob M. The health effects and costs of the interventions to control cardiovascular disease in Kyrgyzstan. 2009. Report No. Akkazieva B, Chisholm D, Akunov N, Jakob M. The health effects and costs of the interventions to control cardiovascular disease in Kyrgyzstan. 2009. Report No.
27.
go back to reference Huang Y, Ren J. Cost-benefit analysis of a community-based stroke prevention program in Bao Shan District, Shanghai, China. Int J Collab Res Intern Med Public Health. 2010;2(9):307–16. Huang Y, Ren J. Cost-benefit analysis of a community-based stroke prevention program in Bao Shan District, Shanghai, China. Int J Collab Res Intern Med Public Health. 2010;2(9):307–16.
28.
go back to reference Ortegon M, Lim S, Chisholm D, Mendis S. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e607.CrossRefPubMedPubMedCentral Ortegon M, Lim S, Chisholm D, Mendis S. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e607.CrossRefPubMedPubMedCentral
29.
go back to reference Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plann. 2011;26(3):210–22.CrossRef Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plann. 2011;26(3):210–22.CrossRef
30.
go back to reference Salomon JA, Carvalho N, Gutierrez-Delgado C, Orozco R, Mancuso A, Hogan DR, et al. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ. 2012;344:e355.CrossRefPubMedPubMedCentral Salomon JA, Carvalho N, Gutierrez-Delgado C, Orozco R, Mancuso A, Hogan DR, et al. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ. 2012;344:e355.CrossRefPubMedPubMedCentral
31.
go back to reference Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti SG, Kopitowski K, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10:627.CrossRefPubMedPubMedCentral Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti SG, Kopitowski K, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10:627.CrossRefPubMedPubMedCentral
32.
go back to reference Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361(9359):717–25.CrossRefPubMed Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361(9359):717–25.CrossRefPubMed
33.
go back to reference Jafar TH, Islam M, Bux R, Poulter N, Hatcher J, Chaturvedi N, et al. Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation. 2011;124(15):1615–25.CrossRefPubMedPubMedCentral Jafar TH, Islam M, Bux R, Poulter N, Hatcher J, Chaturvedi N, et al. Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation. 2011;124(15):1615–25.CrossRefPubMedPubMedCentral
34.
go back to reference Garcia-Pena C, Thorogood M, Wonderling D, Reyes-Frausto S. Economic analysis of a pragmatic randomised trial of home visits by a nurse to elderly people with hypertension in Mexico. Salud Publica Mex. 2002;44(1):14–20.CrossRefPubMed Garcia-Pena C, Thorogood M, Wonderling D, Reyes-Frausto S. Economic analysis of a pragmatic randomised trial of home visits by a nurse to elderly people with hypertension in Mexico. Salud Publica Mex. 2002;44(1):14–20.CrossRefPubMed
35.
go back to reference Lakic D, Petrova G, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Kos M. The cost-effectiveness of hypertension pharmacotherapy in Serbia: a Markov model. Biotechnol Biotechnol Equip. 2014;26(3):3066–72.CrossRef Lakic D, Petrova G, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Kos M. The cost-effectiveness of hypertension pharmacotherapy in Serbia: a Markov model. Biotechnol Biotechnol Equip. 2014;26(3):3066–72.CrossRef
36.
go back to reference Ekwunife OI, Okafor CE, Ezenduka CC, Udeogaranya PO. Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis. Cost Eff Resour Alloc. 2013;11(1):2.CrossRefPubMedPubMedCentral Ekwunife OI, Okafor CE, Ezenduka CC, Udeogaranya PO. Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis. Cost Eff Resour Alloc. 2013;11(1):2.CrossRefPubMedPubMedCentral
37.
go back to reference Anderson AN, Wessels F, Moodley I, Kropman K. AT1 receptor blockers–cost-effectiveness within the South African context. South Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde. 2000;90(5):494–8. Anderson AN, Wessels F, Moodley I, Kropman K. AT1 receptor blockers–cost-effectiveness within the South African context. South Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde. 2000;90(5):494–8.
38.
go back to reference Khonputsa P, Veerman LJ, Bertram M, Lim SS, Chaiyakunnaphruk N, Vos T. Generalised Cost-Effectiveness analysis of pharmaceutical interventions for primary prevention of Cardiovascular disease in Thailand. Value Health Reg Issues. 2012;1(1):15–22.CrossRefPubMed Khonputsa P, Veerman LJ, Bertram M, Lim SS, Chaiyakunnaphruk N, Vos T. Generalised Cost-Effectiveness analysis of pharmaceutical interventions for primary prevention of Cardiovascular disease in Thailand. Value Health Reg Issues. 2012;1(1):15–22.CrossRefPubMed
39.
go back to reference Wang Z, Chen Z, Wang X, Hao G, Ma L, Zhao X, et al. Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China. J Hypertens. 2017;35(4):886–92.CrossRefPubMed Wang Z, Chen Z, Wang X, Hao G, Ma L, Zhao X, et al. Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China. J Hypertens. 2017;35(4):886–92.CrossRefPubMed
40.
go back to reference Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368(9536):679–86.CrossRefPubMedPubMedCentral Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368(9536):679–86.CrossRefPubMedPubMedCentral
41.
go back to reference Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112(23):3569–76.CrossRefPubMed Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112(23):3569–76.CrossRefPubMed
42.
go back to reference Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target-versus risk-based blood pressure treatment. Circulation. 2016;133(9):840–8.CrossRefPubMedPubMedCentral Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target-versus risk-based blood pressure treatment. Circulation. 2016;133(9):840–8.CrossRefPubMedPubMedCentral
43.
go back to reference Gu D, He J, Coxson PG, Rasmussen PW, Huang C, Thanataveerat A, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015;12(8):e1001860.CrossRefPubMedPubMedCentral Gu D, He J, Coxson PG, Rasmussen PW, Huang C, Thanataveerat A, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015;12(8):e1001860.CrossRefPubMedPubMedCentral
44.
go back to reference Araujo DV, Bahia L, Souza C, Pavao A. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS* scenario. Int J Atheroscler. 2007;2(3):189–94. Araujo DV, Bahia L, Souza C, Pavao A. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS* scenario. Int J Atheroscler. 2007;2(3):189–94.
45.
go back to reference Amirsadri M, Hassani A. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men. Daru J Pharm Sci. 2015;23:56.CrossRef Amirsadri M, Hassani A. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men. Daru J Pharm Sci. 2015;23:56.CrossRef
46.
go back to reference Bautista LE, Vera-Cala LM, Ferrante D, Herrera VM, Miranda JJ, Pichardo R, et al. A ‘polypill’ aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Affairs. 2013;32(1):155–64.CrossRefPubMed Bautista LE, Vera-Cala LM, Ferrante D, Herrera VM, Miranda JJ, Pichardo R, et al. A ‘polypill’ aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Affairs. 2013;32(1):155–64.CrossRefPubMed
47.
go back to reference Jarungsuccess S, Taerakun S. Cost-utility analysis of oral anticoagulants for non-valvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand. Clin Ther. 2014;36(10):1389–94.CrossRefPubMed Jarungsuccess S, Taerakun S. Cost-utility analysis of oral anticoagulants for non-valvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand. Clin Ther. 2014;36(10):1389–94.CrossRefPubMed
48.
go back to reference Wu B, Kun L, Liu X, He B. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovasc Drugs Ther. 2014;28(1):87–98.CrossRefPubMed Wu B, Kun L, Liu X, He B. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovasc Drugs Ther. 2014;28(1):87–98.CrossRefPubMed
49.
go back to reference Anderson AN, Moodley I, Kropman K. A South African pharmaco-economic analysis of the Acute Infarction Ramipril Efficacy (AIRE) Study. Cardiovasc J South Afr. 2000;11(2):89–94. Anderson AN, Moodley I, Kropman K. A South African pharmaco-economic analysis of the Acute Infarction Ramipril Efficacy (AIRE) Study. Cardiovasc J South Afr. 2000;11(2):89–94.
50.
go back to reference Permpanicha A, Kulsomboon V, Udol K. Cost-effectiveness analysis of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Asian Biomed. 2015;9(1):21–30. Permpanicha A, Kulsomboon V, Udol K. Cost-effectiveness analysis of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Asian Biomed. 2015;9(1):21–30.
51.
go back to reference Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu D, et al. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. Circ Cardiovasc Qual Outcomes. 2014;7(1):78–85.CrossRefPubMedPubMedCentral Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu D, et al. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. Circ Cardiovasc Qual Outcomes. 2014;7(1):78–85.CrossRefPubMedPubMedCentral
52.
go back to reference Li T, Liu M, Ben H, Xu Z, Zhong H, Wu B. Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. Clin Drug Invest. 2015;35(6):365–74.CrossRef Li T, Liu M, Ben H, Xu Z, Zhong H, Wu B. Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. Clin Drug Invest. 2015;35(6):365–74.CrossRef
53.
go back to reference Pan Y, Wang A, Liu G, Zhao X, Meng X, Zhao K, et al. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. J Am Heart Assoc. 2014;3(3):e000912.CrossRefPubMedPubMedCentral Pan Y, Wang A, Liu G, Zhao X, Meng X, Zhao K, et al. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. J Am Heart Assoc. 2014;3(3):e000912.CrossRefPubMedPubMedCentral
54.
go back to reference Mejia A, Senior JM, Ceballos M, Atehortua S, Toro JM, Saldarriaga C, et al. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia. Biomedica. 2015;35(4):531–40.CrossRefPubMed Mejia A, Senior JM, Ceballos M, Atehortua S, Toro JM, Saldarriaga C, et al. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia. Biomedica. 2015;35(4):531–40.CrossRefPubMed
55.
go back to reference Davies A, Bakhai A, Schmitt C, Barrett A, Graham-Clarke P, Sculpher M. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. J Med Econ. 2013;16(4):510–21.CrossRefPubMed Davies A, Bakhai A, Schmitt C, Barrett A, Graham-Clarke P, Sculpher M. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. J Med Econ. 2013;16(4):510–21.CrossRefPubMed
56.
go back to reference Yan X, Hu HT, Liu S, Sun YH, Gao X. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China. Neurol Res. 2015;37(4):352–8.CrossRefPubMed Yan X, Hu HT, Liu S, Sun YH, Gao X. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China. Neurol Res. 2015;37(4):352–8.CrossRefPubMed
57.
go back to reference Apikoglu Rabus S, Izzettin FV, Sancar M, Rabus MB, Kirma C, Yakut C. Cost-effectiveness of thrombolytics: a simplified model. Pharmacy World Sci (PWS). 2005;27(3):243–8.CrossRef Apikoglu Rabus S, Izzettin FV, Sancar M, Rabus MB, Kirma C, Yakut C. Cost-effectiveness of thrombolytics: a simplified model. Pharmacy World Sci (PWS). 2005;27(3):243–8.CrossRef
58.
go back to reference Araujo DV, Tura BR, Brasileiro AL, Luz Neto H, Pavao AL, Teich V. Cost-effectiveness of prehospital versus inhospital thrombolysis in acute myocardial infarction. Arq Bras Cardiol. 2008;90(2):91–8.CrossRefPubMed Araujo DV, Tura BR, Brasileiro AL, Luz Neto H, Pavao AL, Teich V. Cost-effectiveness of prehospital versus inhospital thrombolysis in acute myocardial infarction. Arq Bras Cardiol. 2008;90(2):91–8.CrossRefPubMed
59.
go back to reference Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A. Cost-effectiveness analysis of fondaparinux vs enoxaparin in non-ST elevation acute coronary syndrome in Thailand. Heart Lung Circ. 2015;24(9):860–8.CrossRefPubMed Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A. Cost-effectiveness analysis of fondaparinux vs enoxaparin in non-ST elevation acute coronary syndrome in Thailand. Heart Lung Circ. 2015;24(9):860–8.CrossRefPubMed
60.
go back to reference Polanczyk CA, Wainstein MV, Ribeiro JP. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil. Arq Bras Cardiol. 2007;88(4):464–74.CrossRefPubMed Polanczyk CA, Wainstein MV, Ribeiro JP. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil. Arq Bras Cardiol. 2007;88(4):464–74.CrossRefPubMed
61.
go back to reference Gonzalez-Diaz B, Garduno-Espinosa J, Salinas-Escudero G, Reyes-Lopez A, Granados-Garcia V. Economic evaluation of the use of drug-eluting stents versus bare-metal stents in adults with ischemic cardiomyopathy requiring angioplasty. Rev Invest Clin. 2015;67(4):219–26.PubMed Gonzalez-Diaz B, Garduno-Espinosa J, Salinas-Escudero G, Reyes-Lopez A, Granados-Garcia V. Economic evaluation of the use of drug-eluting stents versus bare-metal stents in adults with ischemic cardiomyopathy requiring angioplasty. Rev Invest Clin. 2015;67(4):219–26.PubMed
62.
go back to reference Ribeiro RA, Stella SF, Camey SA, Zimerman LI, Pimentel M, Rohde LE, et al. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector. Value Health. 2010;13(2):160–8.CrossRefPubMed Ribeiro RA, Stella SF, Camey SA, Zimerman LI, Pimentel M, Rohde LE, et al. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector. Value Health. 2010;13(2):160–8.CrossRefPubMed
63.
go back to reference Amirsadri M, Sedighi MJ. Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran. Res Pharm Sci. 2017;12(2):144–53.CrossRefPubMedPubMedCentral Amirsadri M, Sedighi MJ. Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran. Res Pharm Sci. 2017;12(2):144–53.CrossRefPubMedPubMedCentral
64.
go back to reference Basu S, Bendavid E, Sood N. Health and economic implications of national treatment coverage for cardiovascular disease in India: cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2015;8(6):541–51.CrossRefPubMedPubMedCentral Basu S, Bendavid E, Sood N. Health and economic implications of national treatment coverage for cardiovascular disease in India: cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2015;8(6):541–51.CrossRefPubMedPubMedCentral
66.
go back to reference Kahende JW, Loomis BR, Adhikari B, Marshall L. A review of economic evaluations of tobacco control programs. Int J Environ Res Public Health. 2009;6(1):51–68.CrossRefPubMed Kahende JW, Loomis BR, Adhikari B, Marshall L. A review of economic evaluations of tobacco control programs. Int J Environ Res Public Health. 2009;6(1):51–68.CrossRefPubMed
67.
go back to reference Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS ONE. 2017;12(3):e0173600.CrossRefPubMedPubMedCentral Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS ONE. 2017;12(3):e0173600.CrossRefPubMedPubMedCentral
68.
go back to reference Pollack HA. Sudden infant death syndrome, maternal smoking during pregnancy, and the cost-effectiveness of smoking cessation intervention. Am J Public Health. 2001;91(3):432–6.CrossRefPubMedPubMedCentral Pollack HA. Sudden infant death syndrome, maternal smoking during pregnancy, and the cost-effectiveness of smoking cessation intervention. Am J Public Health. 2001;91(3):432–6.CrossRefPubMedPubMedCentral
69.
go back to reference Wang LY, Crossett LS, Lowry R, Sussman S, Dent CW. Cost-effectiveness of a school-based tobacco-use prevention program. Arch Pediatr Adolesc Med. 2001;155(9):1043–50.CrossRefPubMed Wang LY, Crossett LS, Lowry R, Sussman S, Dent CW. Cost-effectiveness of a school-based tobacco-use prevention program. Arch Pediatr Adolesc Med. 2001;155(9):1043–50.CrossRefPubMed
70.
go back to reference Tomson T, Helgason AR, Gilljam H. Quitline in smoking cessation: a cost-effectiveness analysis. Int J Technol Assess Health Care. 2004;20(4):469–74.CrossRefPubMed Tomson T, Helgason AR, Gilljam H. Quitline in smoking cessation: a cost-effectiveness analysis. Int J Technol Assess Health Care. 2004;20(4):469–74.CrossRefPubMed
71.
go back to reference Briggs AD, Wolstenholme J, Blakely T, Scarborough P. Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Popul Health Metrics. 2016;14:17.CrossRef Briggs AD, Wolstenholme J, Blakely T, Scarborough P. Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Popul Health Metrics. 2016;14:17.CrossRef
72.
go back to reference Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics. 1998;13(4):397–409.CrossRefPubMed Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics. 1998;13(4):397–409.CrossRefPubMed
73.
go back to reference Blakely T, Cobiac LJ, Cleghorn CL, Pearson AL, van der Deen FS, Kvizhinadze G, et al. Health, health inequality, and cost impacts of annual increases in tobacco tax: multistate life table modeling in New Zealand. PLoS Med. 2015;12(7):e1001856.CrossRefPubMedPubMedCentral Blakely T, Cobiac LJ, Cleghorn CL, Pearson AL, van der Deen FS, Kvizhinadze G, et al. Health, health inequality, and cost impacts of annual increases in tobacco tax: multistate life table modeling in New Zealand. PLoS Med. 2015;12(7):e1001856.CrossRefPubMedPubMedCentral
74.
go back to reference Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ. 2002;11(1):23–31.CrossRefPubMed Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ. 2002;11(1):23–31.CrossRefPubMed
75.
go back to reference Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Syst Rev. 2017;2:Mr000033. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Syst Rev. 2017;2:Mr000033.
76.
go back to reference Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–30.CrossRefPubMedPubMedCentral Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–30.CrossRefPubMedPubMedCentral
77.
go back to reference Remme M, Martinez-Alvarez M, Vassall A. Cost-effectiveness thresholds in global health: taking a multisectoral perspective. Value Health. 2017;20(4):699–704.CrossRefPubMed Remme M, Martinez-Alvarez M, Vassall A. Cost-effectiveness thresholds in global health: taking a multisectoral perspective. Value Health. 2017;20(4):699–704.CrossRefPubMed
78.
go back to reference Tantivess S, Chalkidou K, Tritasavit N, Teerawattananon Y. Health technology assessment capacity development in low- and middle-income countries: experiences from the international units of HITAP and NICE. F1000Research. 2017;6:2119.CrossRefPubMedPubMedCentral Tantivess S, Chalkidou K, Tritasavit N, Teerawattananon Y. Health technology assessment capacity development in low- and middle-income countries: experiences from the international units of HITAP and NICE. F1000Research. 2017;6:2119.CrossRefPubMedPubMedCentral
79.
go back to reference Odame EA. Systematic review of economic evaluation literature in Ghana: Is health technology assessment the future? Value Health Reg Issues. 2013;2(2):279–83.CrossRefPubMed Odame EA. Systematic review of economic evaluation literature in Ghana: Is health technology assessment the future? Value Health Reg Issues. 2013;2(2):279–83.CrossRefPubMed
80.
go back to reference Doherty JE, Wilkinson T, Edoka I, Hofman K. Strengthening expertise for health technology assessment and priority-setting in Africa. Glob Health Action. 2017;10(1):1370194.CrossRefPubMedPubMedCentral Doherty JE, Wilkinson T, Edoka I, Hofman K. Strengthening expertise for health technology assessment and priority-setting in Africa. Glob Health Action. 2017;10(1):1370194.CrossRefPubMedPubMedCentral
81.
go back to reference Glassman A, Chalkidou K, Giedion U, Teerawattananon Y, Tunis S, Bump JB, et al. Priority-setting institutions in health: recommendations from a center for global development working group. Glob Heart. 2012;7(1):13–34.CrossRefPubMed Glassman A, Chalkidou K, Giedion U, Teerawattananon Y, Tunis S, Bump JB, et al. Priority-setting institutions in health: recommendations from a center for global development working group. Glob Heart. 2012;7(1):13–34.CrossRefPubMed
82.
go back to reference Aminde LN, Atem JA, Kengne AP, Dzudie A, Veerman JL. Body mass index-measured adiposity and population attributability of associated factors: a population-based study from Buea, Cameroon. BMC Obes. 2017;4:1.CrossRefPubMedPubMedCentral Aminde LN, Atem JA, Kengne AP, Dzudie A, Veerman JL. Body mass index-measured adiposity and population attributability of associated factors: a population-based study from Buea, Cameroon. BMC Obes. 2017;4:1.CrossRefPubMedPubMedCentral
83.
go back to reference Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ manual: 2014: the systematic review of economic evaluation evidence. South Australia: Joanna Briggs Inst; 2014. Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ manual: 2014: the systematic review of economic evaluation evidence. South Australia: Joanna Briggs Inst; 2014.
Metadata
Title
Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations
Authors
Leopold Ndemnge Aminde
Noah Fongwen Takah
Belen Zapata-Diomedi
J. Lennert Veerman
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2018
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/s12962-018-0108-9

Other articles of this Issue 1/2018

Cost Effectiveness and Resource Allocation 1/2018 Go to the issue